ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
These iPSC lines, developed by ALS TDI from samples generously donated by participants in the ALS Research Collaborative (ARC) Study, represent both genetic and sporadic forms of ALS. They include key ALS-associated mutations such as C9orf72, SOD1, and TDP-43, and will be used to generate ALS-relevant cell types—including motor neurons, microglia, and astrocytes—for use in drug discovery and disease modeling.
The goal of this collaboration is to provide high-quality research tools to the global scientific community, including academic and pharmaceutical researchers, to help further the understanding and development of treatments for ALS.
'This is a major step forward for ALS research,' said Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. 'By making these iPSC-derived cells broadly accessible through Axol's infrastructure, we are ensuring that the contributions of people with ALS who shared their samples and data through ARC can drive discoveries in labs across the globe.'
ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available today. These cells are derived from real people living with ALS, many of whom also shared clinical data, creating a uniquely valuable resource for understanding disease mechanisms and testing potential treatments.
Through this agreement, Axol will manufacture and distribute iPSC-derived cells to academic and industry researchers worldwide, ensuring quality, consistency, and scalability. The goal, to accelerate progress across the ALS field by providing powerful, human-relevant tools that better reflect the diversity and complexity of the disease.
'Collaborating with ALS-TDI allows us to broaden access to highly disease-relevant iPSC models of ALS, which are vital for understanding disease mechanisms and accelerating therapeutic discovery for patients and their families,' said Liam Taylor, CEO of Axol Bioscience. 'This partnership aligns with our mission to build and enable better human disease models by providing high-quality, human-relevant cells and models that advance neuroscience research and drug development.'
ALS TDI extends its deepest thanks to every person living with ALS who contributed to this effort. Their willingness to share samples and data through the ARC Study has made this breakthrough possible.
To learn more about the ALS Research Collaborative, visit www.als.net/arc.
For more information, please contact:
Axol Bioscience
Duncan Borthwick
[email protected]
www.axolbio.com
ALS Therapy Development Institute
Fernando Vieira
[email protected]
www.als.net
About Axol Bioscience
Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. Axol has a deep connection with the ALS research community and works to support the creation of more human relevant in vitro models to accelerate discovery and therapeutic development.
About ALS Therapy Development Institute (ALS TDI)
The ALS Therapy Development Institute (ALS TDI) is the world's first and largest nonprofit biotech dedicated solely to discovering and developing effective treatments for ALS. Based in Watertown, Massachusetts, ALS TDI runs a state-of-the-art research center and leads the ALS Research Collaborative (ARC)—one of the most comprehensive and longest-running natural history studies in ALS. Through innovative, patient-driven science, ALS TDI is working to end ALS for everyone affected by this devastating disease.
Contact Information:
ALS Therapy Development Institute
Meghan Lawlor
(978)729-2961
Contact via Email
www.als.net
Read the full story here: ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a minute ago
- Medscape
GVHD in Children: What Dermatologists Need to Know
SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including the cutaneous manifestations of graft-vs-host disease (GVHD), according to Jennifer T. Huang, MD, associate professor of dermatology and pediatrics, Harvard Medical School, Boston. GVHD is the most common complication following HSCT, and while it can affect any body organ, the skin is the most commonly involved. 'In the US, there are 85 centers in 37 states that perform pediatric allogeneic transplants,' Huang said at the Society for Pediatric Dermatology (SPD) 2025 Annual Meeting. In the US, about 1400 allogeneic transplants are performed each year, and 15% are in children, she noted. While HSCT is generally associated with cancer treatment, in about one third of cases in children, allogeneic HSCT is used to treat nonmalignant conditions such as bone marrow failure, primary immunodeficiency, and hemoglobinopathy. Currently, 5-year survival after pediatric allogeneic HSCT ranges from 50% to 90%, said Huang, who is also director of pediatric oncodermatology at Boston Children's Hospital, Boston. As a result, dermatologists may be seeing more cases of not only cutaneous manifestations of GVHD but also other HSCT-associated effects, such as persistent hair loss and skin cancer. The grading criteria for acute GVHD are well established for the skin, liver, and intestinal tract effects. For the skin, severity is staged based on the percentage of body surface area affected by a rash and the presence or absence of blistering. Generalized erythroderma and the presence of blisters indicate a more severe stage of GVHD. When it presents with symptoms such as generalized erythroderma, desquamation, and bullae, acute, severe GVHD can mimic toxic epidermal necrolysis (TEN), a severe drug-induced skin reaction characterized by widespread epidermal necrosis. Because transplant recipients often take many medications, it can be difficult to distinguish between the two conditions. TEN-like GVHD is rare, noted Huang, a co-author of a case series and literature review of TEN-like acute GVHD in pediatric bone marrow transplant patients. 'Of the 10 patients in the series with TEN-like GVHD, seven had other organ involvement, and 80% died,' she said. Managing Acute GVHD When managing a patient with acute GVHD with cutaneous manifestations, a biopsy may not be very helpful. She referred to a small study conducted at Boston Children's Hospital of 27 children who underwent a biopsy for skin eruptions suspicious for acute GVHD. The biopsy yielded a definitive diagnosis of GVHD or other disorder in only four (15%) cases and changed management in only two patients. In contrast, a dermatology consultation was associated with changes in clinical management in nearly 80% of the patients (21 of the 27) compared with 7.4% (2 of the 27) of skin biopsy results. 'We should be careful about doing biopsies in these patients, unless you think that there's another diagnosis that's a slam dunk histopathological diagnosis like leukemia cutis,' she said. 'Otherwise, you cannot differentiate GVHD from drug rash or viral exanthem, and you should rely on your clinical signs and symptoms.' Second, dermatologists need to know the details of the transplant to evaluate the risk, and third, 'look for acral involvement and systemic symptoms to lead you to the diagnosis, and don't rely on skin biopsy,' she said. 'Importantly, treat aggressively and early, especially if there is TEN-like GVHD.' Chronic GVHD Acute GVHD is the most important risk factor for developing chronic GVHD, a complex, multisystem disorder that is distinct from acute GVHD, with features that resemble autoimmune and other immunologic conditions. 'I think of chronic GVHD as alloimmunity,' Huang explained. Continuing inflammation activates an 'alloresponse,' resulting in the development of what appears to be an autoimmune disease affecting the skin and other organs 'as a response to chronic inflammation,' she said. Chronic skin GVHD most commonly presents in children with eczematous, sclerotic, or lichenoid skin changes and can often be diagnosed clinically without a biopsy in many cases. If a patient presents with diagnostic features such as poikiloderma, lichen planus-like features, sclerotic features, morphea-like features, and lichen sclerosus-like features, biopsy confirmation is generally not required, she noted. Regardless of whether it's acute or chronic, there are minimal histopathologic criteria for diagnosing active GVHD, Huang said. These include the presence of apoptosis in the epidermal basal layer or lower Malpighian layer or outer root sheath of hair follicles, or acrosyringium, lichenoid inflammation, vacuolar changes, and lymphocytic satellitosis. Management of chronic GVHD is usually multifactorial, with three main goals: to improve quality of life (addressing symptoms, daily activities, and visible changes); to minimize systemic immunosuppression; and to avoid permanent disfigurement. 'There are effective topical therapies for skin GVHD that can minimize systemic immunosuppression, and these can often do the trick,' which include steroids, as well as tacrolimus and ruxolitinib, she said. Preventive measures are underutilized, such as gentle care for dry skin, treating other rashes, and, very importantly, sun protection, because sunburn can trigger GVHD, she added. Phototherapy is also a good therapeutic option for skin-directed therapy. In addition, there are now several FDA-approved targeted therapies for chronic GVHD in children, including ibrutinib, ruxolitinib, belumosudil, and axatilimab. 'As dermatologists, we can also guide therapy with biologics that we feel comfortable with but that our other colleagues may not know much about,' said Huang. 'Let's maximize skin-directed therapies for treating this disease. We don't want to lose the graft, and we also don't want permanent disfigurement — this has a lot to do with recognizing the disease early and treating it aggressively.' Huang reported having no relevant financial relationships or conflicts of interest.
Bloomberg
2 minutes ago
- Bloomberg
The CDC Shooting Proves How Dangerous Misinformation Can Be
The horrifying attack on the Centers for Disease Control and Prevention's Atlanta headquarters felt like the grimly predictable result of years of pandemic-related misinformation and disinformation — much of it propagated by the very people now leading US health agencies. It's no surprise, then, that instead of offering a concrete plan to protect staff and rebuild public trust, Health and Human Services Secretary Robert F. Kennedy Jr. seized the tragedy as another opportunity to double down on his dangerous rhetoric.
Washington Post
2 minutes ago
- Washington Post
Meet my new hairstylist: Cancer
It's not clear why chemotherapy gave me curls, but when life gives you Garfunkel … It's still not me in the mirror. It's obviously my teeth being brushed with my toothbrush. Who else's face would it be, holding the mouth with my teeth in it? Outside, I see my shadow and then look around for Little Orphan Annie. A year and a half ago, at 39, I qualified for the 'adolescents and young adults' category of cancer patients. It's nice to still be precocious! The breast cancer survivorship predictions that my doctors showed me were all fairly reassuring, as these things go, especially since I chose to get chemotherapy. But the statistics we have are all based on previous generations that didn't tend to get cancer this young. Nobody knows why this is happening. Story continues below advertisement Anyway, I went bald. It was an adventure. I was aerodynamic. The shower drain never needed cleaning. More strangers complimented my head than ever in my life. I liked it, too, as an experiment with a defined end point: Life would return to normal. When chemo ended, I would not, and my hair would come back. It did not. Hair came back, but it was someone else's hair. Thicker, fluffier — and curly. The hair, in fact, that I had tried for years to achieve, without success. Thanks, cancer! The writer holds a photo of herself with no hair, holding a photo of herself with long, straight hair. (Allison Robbert/For The Washington Post) As a youth, I was disappointed by the hair I'd always had; it was mismatched with what I felt my hair should be. Wild. Untamed. Anything but droopy, flat and always the same. The hair my brain recognizes as mine was also Marcia Brady's, except thinner. Three feet long, straight, never ever gonna curl or have body or volume. I wasn't born knowing that. I spent decades going to CVS, looking uncertainly at one product or another. A kind of corn starch you massaged into your roots. Or a 400-degree crimper. Or various goos and sprays and objects you wrap your hair around. These came home with me for another episode of 'The Hair That Wouldn't Do Squat.' Now, the hair does everything. In 360 degrees. All at once. Marcia Brady is gone from my mirror, and Richard Simmons is in her place. Ask the internet, and medical sites tell you that chemotherapy sometimes changes your hair follicles. Also, it sometimes doesn't. And these changes last about nine months, or two years, or some other amount of time, including forever. A lack of published scientific information about chemo curls didn't stop expert scientific explainer guy Hank Green from finding out more. He undertook his own in vivo experiment, subjecting himself to chemotherapy in the name of science, and also because he had Hodgkin's lymphoma. The experiment worked: He emerged a cancer-free, curly-haired man (though he has straightened back out now). 'It might have something to do with the shape of the follicle or the proteins being produced, or how the cells are arranged in there as they heal,' he says. 'But as of now, we don't really know.' Story continues below advertisement Advertisement It gets weirder: Chemo enabled him to grow a beard, whereas before he only shaved once a week. People online have reported that their curls also change with birth control, pregnancy and gender transition. The New Yorker has a story about chemo essentially curing a woman's schizophrenia. Curls are fluff. This isn't where we should spend our disappearing science funding. And a study won't tell me what I want to know, which is that my curls will stay this way at least long enough for me to Figure Out Curls. Several lifetimes' worth of watching TikToks await. Plus, I do situational research. Recently, when a ringleted Apple Store guy asked if he could help me, the first thing I said was, 'What is your curl routine?' He said shampoo once a week. Score. The writer's curls. (Allison Robbert/For The Washington Post) At first, my hair came back as you'd expect, as the softest stubble. At about half an inch, though, there started to be a distinct ripple. The ripple evolved into '90s Billy Crystal (I clearly was not specific enough when I wished for the hair in 'When Harry Met Sally…'). There was a Nancy Reagan moment. And since then, it has gotten darker — and more and more (and more) poodle. I call this the haircut nobody asks for, or Baby's First 'Do. It has changed the shape of my face. Old friends don't recognize me. They seem to share some of the discomfort I feel standing in front of the mirror: Who is this? It's like I uncanny-valleyed myself. As soon as I knew that my diagnosis probably wouldn't kill me, I started focusing on the moment I could go back to being the me who wasn't sick (or more precisely, and cruelly: the me who did not know she was sick). Cancer friends (that's a category now) reassured me it would happen. But the curls have blocked my fantasy that I could be the same person again. They force me to transition from 'surviving' to 'survivor.' Chemo did a bunch of things besides maybe saving my life. It aged my skin, weakened my bones and made me have to pee about twice as frequently. One of my eyebrows didn't really come back. I get shots to keep me in menopause. Fear makes me draw a mark on my leg where I feel a bone ache, and take a picture so I know if it's in the same place the next time it aches. Bones are often where breast cancer metastasizes. Whether I accept it or not, I am old. Older. But there's only one way not to get older — surprise, it's dying — and I faced it last year. I took poison in hopes of someday looking good for 55. I'd prefer it not be, like, today. Story continues below advertisement Advertisement After months of treatment and feeling, oh, let's call it liberated from the concept of pretty, it's wonderfully odd to have a whole new kind of pretty dropped on my shoulders. It has also been pretty great to have a reconstruction surgeon earnestly asking me what kind of breasts I would like. (WHERE WAS HE WHEN I WAS 15?) It's been a kind of strange reverse-puberty. New hair, boobs and hormones! Everyone treats you differently now! The woman who didn't know she had cancer had mastered denial. She was almost absurdly, determinedly carefree, driving a 23-year-old car and being astonished when it broke down. She didn't go to the doctor regularly. She didn't even have a doctor. Nothing bad could happen to her. The disease fed on her immaturity. I don't get to be her anymore. I have to grow up, and acknowledge that it's really me in the mirror. But to the extent that hair is identity, getting a new mirror image at 41 is a gift. I'm a new me in a way that isn't gray and wrinkles and aches. And I have no idea — none at all — what I'll look like, what I'll be, in three months. Talk about staying young. Story continues below advertisement Advertisement My face isn't mine in the mirror, but the hair finally, somehow, matches my spirit. She is wild. She is a gift. A lifeline that I'm not getting more staid in middle age. A bridge, you might say — but also some troubled water.…
